It was developed in the Weizmann Institute of Science in Israel by Michael Sela, Ruth Arnon and Deborah Teitelbaum.[17][18] Development of the Interferon proteins by Michel Revel from the Weizmann Institute of Science in Israel.[19] Development of taliglucerase alfa (Elelyso), a recombinant glucocerebrosidase enzyme produced from transgenic carrot cell cultures.[20] Taliglucerase alfa won approval from the U.S. Food and Drug Administration in May 2012 as an orphan drug for the treatment of Type 1 Gaucher's disease.[21] Development of Chimeric Antigen Receptor